---
document_datetime: 2026-02-05 15:21:18
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/dasatinib-accord-healthcare-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: dasatinib-accord-healthcare-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 7.2173299
conversion_datetime: 2026-02-09 22:17:32.763762
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.1
  docling: 2.72.0
  docling-core: 2.63.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## DasatinibAccordHealthcare

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber    | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation typeIA_IN/ | This was an application for a group of | 04/02/2026                          |                                          | Annex II and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000324500                     | variations. Q.II.b.2.c)Addition orreplacement of a site responsible forbatchrelease(QP certification)-Q.11.b.2.c.2Including batch control/testing applying physicochemical and/ormicrobiological analyticalprocedures for the finished product - Accepted Q.II.b.1 Change in the manufacturing site for part or all of the manufacturing process of thefinishedproduct(exceptforbatch releaseandbatchcontrol testing sites)- Q.I1.b.1.a)Addition or replacement of a site responsible for secondary packaging - Accepted   |            |     | PL   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| Variation type IA / EMA/VR/0000316016 | A.5Change in the name and/or addressof a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted                                                                                                                                                                                                                                                        | 16/12/2025 | N/A |      |
| Variation type IB / EMA/VR/0000306994 | - - Accepted C.I.11.z-to update the RMP forDasatinib Accord Healthcare in line with European Public Assessment Report (EPAR) for RMP of reference product Sprycel (Dasatinib) (version 18.2, dated 29-Apr-2024) published                                                                                                                                                                                                                                                                                                  | 12/11/2025 | N/A |      |

<div style=\"page-break-after: always\"></div>

|                                          | ontheEMAwebsiteon18June2025.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |                        |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|
| Variation type IA_IN / EMA/VR/0000288694 | This was an application for a group of variations. B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1 Change within therange of the currently approved pack sizes-Accepted B.II.e.5.a Change in the number of units (e.g.tablets, ampoules,etc.) in a pack - B.1I.e.5.a.1 Change within the range of the currently approvedpacksizes-Accepted B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1 Change within the range of the currentlyapprovedpacksizes-Accepted B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1 Change within the range of the currently approved pack sizes - Accepted B.II.e.5.aChangeinthenumberofunits (e.g. tablets, ampoules, etc.) in a pack - B.1I.e.5.a.1 Change within the range of the currently approvedpacksizes-Accepted B.II.e.5.a Change in the number of units | 19/08/2025 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| B.1I.e.5.a.1 Change within the range of the currently approved pack sizes - Accepted   |
|----------------------------------------------------------------------------------------|